Thyroid dysfunction from inhibitor of fibroblast growth factor receptor

BACKGROUND: Thyroid dysfunction has not been previously reported in clinical trials of selective fibroblast growth factor receptor (FGFR) inhibitors including AZD4547. Herein, we report a case of worsening hypothyroidism in a patient with advanced urothelial cancer treated with AZD4547. CASE PRESENT...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Jeffrey, Moyers, Justin, Wong, John, Hsueh, Chung-Tsen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379924/
https://www.ncbi.nlm.nih.gov/pubmed/30820365
http://dx.doi.org/10.1186/s40164-019-0130-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379924/
https://www.ncbi.nlm.nih.gov/pubmed/30820365
http://dx.doi.org/10.1186/s40164-019-0130-4

Ejemplares similares